

# Design, Synthesis, and Biological Activities of Aromatic Gossypol Schiff Base Derivatives

Ling Li,<sup>†</sup> Zheng Li,<sup>†</sup> Kailiang Wang,<sup>†</sup> Sheng Zhao,<sup>#</sup> Jiming Feng,<sup>#</sup> Jiarui Li,<sup>§</sup> Peiwen Yang,<sup>§</sup> Yuxiu Liu,<sup>†</sup> Lizhong Wang,<sup>†</sup> Yongqiang Li,<sup>\*,†</sup> Hui Shang,<sup>\*,§</sup> and Qingmin Wang<sup>\*,†</sup>

<sup>†</sup>State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin 300071, People's Republic of China

<sup>§</sup>Agricultural Environment and Resources Institute, Yunnan Academy of Agricultural Sciences, Yunnan 650205, People's Republic of China

<sup>#</sup>China Tobacco Yunnan Import and Export Company, Ltd., Yunnan 650031, People's Republic of China

## **S** Supporting Information

**ABSTRACT:** A series of aromatic gossypol Schiff bases have been successfully synthesized via a feasible chemical modification. The antiviral activity against tobacco mosaic virus (TMV) of these gossypol Schiff bases has been tested for the first time. The bioassay studies indicated most of these derivatives exhibited excellent anti-TMV activity, in which *o*-trifluoromethylaniline Schiff base (**19**) displayed the best antiviral activities. Furthermore, compound **19** exhibited an eminent anti-TMV effect in the field and low toxicity to mice. These results suggest it is a promising candidate for the inhibitor of plant virus.

**KEYWORDS:** gossypol, Schiff base, synthesis, anti-TMV activity, structure–activity relationships

## ■ INTRODUCTION

The discovery of gossypol (**1**, Figure 1) has attracted considerable attention due to its applications in antitumor activity.<sup>1</sup> Such a compound embedded in the cottonseed pigment glands exists in three forms,<sup>2</sup> which can be categorized as the aldehyde tautomer **1a**, the ketone (quinoid) tautomer **1b**, and the lactol (hemiacetal) tautomer **1c** (Figure 1). In most cases, as a part of the plant's defense system against pathogens (*Verticillium dahliae*, *Rhizoctonia solani*, and *Xanthomonas campestris*)<sup>3</sup> and herbivorous insects such as *Spodoptera* species and *Heliothis* species,<sup>4</sup> gossypol exhibits multiple biological properties,<sup>1d</sup> including spermicidal, antitumor, antiparasitic, and antiprotozoan activities. It also reported to have antiviral activity toward enveloped viruses such as HIV-1,<sup>5</sup> H<sub>5</sub>N<sub>1</sub>,<sup>5</sup> HSV-2,<sup>6</sup> and influenza virus<sup>7</sup> rather than nonenveloped viruses, such as poliovirus. However, a recent patent revealed that the gossypol fatty acid reagent had antiviral activity against tobacco mosaic virus (TMV),<sup>8</sup> which is classified as a nonenveloped virus.

The plant disease caused by TMV is found worldwide. It is well-known that TMV can infect members of 36 plant families and at least 400 individual species, including tobacco, tomato, pepper, cucumber, and a number of ornamental flowers.<sup>9</sup> TMV disease can cause vast losses in agriculture. It is found that in certain fields 90–100% of the plants showed mosaic or leaf necrosis by harvesting time. Ribavirin is one of the most widely used plant virus inhibitors, even though its inhibitory effects are <50% at 500 μg/mL. Ningnanmycin, perhaps the most successful registered antiplant viral agent, displayed a 56% in vivo curative effect at 500 μg/mL. Recently, a number of chemicals<sup>10</sup> were reported to exhibit antiviral activities; however, few of them have been utilized successfully in

agriculture. As a result, the field of TMV inhibitors still deserves to be further exploited.

Knowledge of the molecular mechanism of the biological effects for gossypol is still limited. Some literature studies show that gossypol exerts its pharmacological actions by an interaction with biomolecular targets, such as enzymes, signal transduction mediators, or membranes.<sup>11</sup> Kovacic<sup>12</sup> in 2003 discussed the mechanism of biological properties of gossypol as well and pointed out that gossypol and its metabolites could produce reactive oxygen species (ROS) through redox cycling by electron transfer functions. Additionally, Bacsó in 2011 reported that external application of ROS in tobacco may control virus replication and symptom development.<sup>13</sup> On the basis of such interpretation, the antiviral activity of gossypol toward a nonenveloped virus, TMV, can be inferred as being relevant to ROS.

Numerous studies suggest gossypol is toxic to monogastric animals, but its toxicity can be reduced while its therapeutic effects are retained by modification of gossypol's reactive aldehyde groups.<sup>14</sup> A few gossypol Schiff bases were synthesized and tested for their biological activities including antitumor, antimalaria, and interferon-inducing activities.<sup>15</sup> However, reports of the anti-TMV activity of the gossypol Schiff bases are rather rare, and no examples are documented in the recent literature.<sup>5,15,16</sup> Gossypol analogues with quinones and conjugated imine groups have electron transfer functionalities to generate ROS, which may control virus replication and symptom development.<sup>13</sup> Therefore, condensation products of

**Received:** September 13, 2014

**Revised:** October 24, 2014

**Accepted:** October 29, 2014




Figure 1. Structures of gossypol and its tautomeric forms.




Figure 2. Design of compounds 3–25.

gossypol and aromatic amines are expected to adjust gossypol to produce ROS and thus modulate the anti-TMV activity level. (Figure 2) In this contribution, a family of aromatic gossypol Schiff base derivatives has been synthesized and their anti-TMV activities have been determined using both *in vitro* and *in vivo* test methods. The structure–activity relationships of these derivatives were discussed as well. Field trial and toxicity evaluation were also conducted for the compound with high anti-TMV activity primarily to assess its potential as an antiviral candidate. Additionally, the synthesized derivatives were also investigated for their potential as fungicidal, insecticidal, or herbicidal reagents (see the Supporting Information).

## MATERIALS AND METHODS

**General.** Reagents were purchased from commercial sources and were used as received. All anhydrous solvents were dried and purified by standard techniques just before use. Reaction progress was monitored by thin-layer chromatography on silica gel GF-254 with detection by UV. Melting points were determined on an X-4 binocular microscope melting point apparatus and are uncorrected.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded on a Bruker Ascend 300/400 MHz spectrometer. Chemical shift values ( $\delta$ ) are given in parts per million and downfield from internal tetramethylsilane. High-resolution mass spectra (HRMS) were recorded on FT-ICR MS (Ionspec, 7.0 T).

**General Procedure for the Synthesis of Aromatic Gossypol Schiff Bases 3–10, 12–14, 19, 21, 22, 24, and 25.** A solution of gossypol acetic acid (2, 0.50 g, 0.86 mmol) and aromatic amine (1.73 mmol) in ethanol (50 mL) was stirred and refluxed for 5 h, and then the reaction mixture was cooled to room temperature. The resulting

solid was filtered, washed with ethanol, and recrystallized to give the desired gossypol derivatives.

**General Procedure for the Synthesis of Aromatic Gossypol Schiff Base Derivatives 11 and 23.** A mixture of aromatic amine (1.73 mmol), NaOH (2.59 mmol), and ethanol (50 mL) was stirred and refluxed for 1 h. Then gossypol acetic acid (2, 0.50 g, 0.86 mmol) was added, and the reaction liquid was refluxed for a further 5 h. The reaction mixture was cooled to room temperature, and then the resulting solid was filtered, washed with ethanol, and then recrystallized to give the desired gossypol derivatives.

**General Procedure for the Synthesis of Aromatic Gossypol Schiff Bases 15–18 and 20.** A solution of gossypol acetic acid (2, 0.50 g, 0.86 mmol) and aromatic amine (3.46 mmol) in ethanol (50 mL) was stirred and refluxed for 5 h and then the reaction mixture was cooled to room temperature. The resulting solid was filtered, washed with ethanol, and then recrystallized to give the desired gossypol derivatives.

**Data for 3:** chocolate crystal recrystallized from benzene; yield, 95%; mp, 252–253 °C (lit.<sup>17</sup> 258–260 °C);  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ),  $\delta$  14.92 (d,  $J = 12.3$  Hz, 2H), 10.18 (d,  $J = 12.3$  Hz, 2H), 7.88 (s, 2H), 7.63 (s, 2H), 7.41–7.28 (m, 8H), 7.18 (t,  $J = 7.1$  Hz, 2H), 5.76 (s, 2H), 3.79–3.67 (m, 2H), 2.16 (s, 6H), 1.58–1.53 (m, 12H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ),  $\delta$  174.34, 154.14, 149.39, 147.00, 139.47, 132.76, 129.87, 129.78, 128.76, 125.88, 118.68, 118.21, 116.31, 114.46, 105.09, 27.57, 20.32, 20.29, 20.10; HRMS (ESI) calcd for  $\text{C}_{42}\text{H}_{39}\text{N}_2\text{O}_6$  ( $M - \text{H}^-$ ) 667.2814, found 667.2812.

**Data for 4:** orange crystal recrystallized from chloroform; yield, 95%; mp, 246–248 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  14.97 (d,  $J = 12.4$  Hz, 2H), 10.15 (d,  $J = 12.4$  Hz, 2H), 7.91 (s, 2H), 7.63 (s, 2H), 7.23–7.13 (m, 8H), 5.74 (s, 2H), 3.80–3.69 (m, 2H), 2.33 (s, 6H), 2.15 (s, 6H), 1.58–1.53 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$

173.91, 154.21, 149.35, 147.03, 137.00, 135.95, 132.61, 130.42, 129.66, 128.49, 118.62, 118.14, 116.17, 114.49, 104.84, 27.55, 20.94, 20.35, 20.31, 20.13; HRMS (ESI) calcd for  $C_{44}H_{43}N_2O_6$  (M - H)<sup>-</sup> 695.3127, found 695.3139.

**Data for 5:** dark orange crystal recrystallized from tetrahydrofuran and ethanol; yield, 60%; mp, 272–274 °C (lit.<sup>18</sup> 287–289 °C); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 15.08 (d, J = 12.0 Hz, 2H), 10.09 (d, J = 12.0 Hz, 2H), 7.90 (s, 2H), 7.63 (s, 2H), 7.24 (d, J = 9.0 Hz, 4H), 6.89 (d, J = 9.0 Hz, 4H), 5.75 (s, 2H), 3.79 (s, 6H), 3.77–3.70 (m, 2H), 2.15 (s, 6H), 1.57–1.54 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 173.44, 157.94, 154.43, 149.30, 147.03, 132.82, 132.48, 129.54, 128.31, 119.65, 118.56, 116.09, 115.09, 114.50, 104.74, 55.59, 27.54, 20.37, 20.33, 20.13; HRMS (ESI) calcd for  $C_{44}H_{45}N_2O_8$  (M + H)<sup>+</sup> 729.3170, found 729.3163.

**Data for 6:** orange crystal recrystallized from pyridine; yield, 79%; mp, 241–243 °C (lit.<sup>19</sup> 291 °C); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 15.18 (d, J = 11.8 Hz, 2H), 10.30 (d, J = 11.8 Hz, 2H), 9.66 (s, 2H), 8.52 (s, 2H), 8.15 (s, 2H), 7.51 (s, 2H), 7.21 (d, J = 8.8 Hz, 4H), 6.83 (d, J = 8.8 Hz, 4H), 3.79–3.70 (m, 2H), 1.99 (s, 6H), 1.49–1.44 (m, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 172.52, 155.74, 153.64, 149.98, 146.16, 132.00, 131.27, 127.99, 127.47, 120.75, 119.36, 116.90, 116.46, 115.49, 104.98, 26.56, 20.27, 20.24, 20.21; HRMS (ESI) calcd for  $C_{42}H_{39}N_2O_8$  (M - H)<sup>-</sup> 699.2712, found 699.2712.

**Data for 7:** yellow crystal recrystallized from pyridine and ethanol; yield, 78%; mp, 266 °C (dec) (lit.<sup>20</sup> 203–204 °C); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 14.96 (d, J = 11.6 Hz, 2H), 10.31 (d, J = 11.6 Hz, 2H), 8.54 (s, 2H), 8.22 (s, 2H), 7.52 (s, 2H), 7.45–7.38 (m, 4H), 7.30 (t, J = 8.5 Hz, 4H), 3.79–3.71 (m, 2H), 2.00 (s, 6H), 1.49–1.43 (m, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 173.56, 160.93, 158.52, 153.87, 150.11, 146.10, 136.30, 132.46, 128.86, 127.77, 121.16, 119.83, 119.75, 117.10, 116.89, 116.66, 115.35, 105.61, 26.60, 20.22, 20.19; HRMS (ESI) calcd for  $C_{42}H_{37}F_2N_2O_6$  (M - H)<sup>-</sup> 703.2625, found 703.2603.

**Data for 8:** yellow crystal recrystallized from chloroform and ethanol; yield, 64%; mp, 286–287 °C (lit.<sup>19</sup> 302 °C); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.95 (d, J = 12.0 Hz, 2H), 10.09 (d, J = 12.0 Hz, 2H), 7.82 (s, 2H), 7.63 (s, 2H), 7.33 (d, J = 8.6 Hz, 4H), 7.23 (d, J = 8.6 Hz, 4H), 5.75 (s, 2H), 3.80–3.64 (m, 2H), 2.15 (s, 6H), 1.56–1.53 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 174.65, 153.69, 149.37, 146.90, 138.13, 133.01, 131.13, 129.97, 129.91, 129.13, 119.29, 118.82, 116.29, 114.21, 105.30, 27.58, 20.28, 20.24, 20.10; HRMS (ESI) calcd for  $C_{42}H_{37}Cl_2N_2O_6$  (M - H)<sup>-</sup> 735.2034, found 735.2034.

**Data for 9:** orange-red crystal recrystallized from pyridine and ethanol; yield, 81%; mp, 284–286 °C (lit.<sup>19</sup> 305–306 °C); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.84 (d, J = 11.7 Hz, 2H), 10.12 (d, J = 11.7 Hz, 2H), 8.24 (d, J = 9.0 Hz, 4H), 7.69 (s, 2H), 7.64 (s, 2H), 7.36 (d, J = 9.0 Hz, 4H), 5.82 (s, 2H), 3.75–3.66 (m, 2H), 2.17 (s, 6H), 1.58–1.52 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 176.46, 155.92, 151.73, 149.87, 149.67, 146.75, 137.66, 135.94, 134.01, 130.47, 125.94, 123.74, 117.51, 107.20, 106.02, 27.69, 20.19, 20.14, 20.12; HRMS (ESI) calcd for  $C_{42}H_{38}Na_4NaO_{10}$  (M + Na)<sup>+</sup> 781.2480, found 781.2486.

**Data for 10:** gold crystal recrystallized from pyridine and ethanol; yield, 79%; mp, 261–263 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.89 (d, J = 11.2 Hz, 2H), 10.15 (d, J = 12.0 Hz, 2H), 7.77 (s, 2H), 7.65–7.55 (m, 6H), 7.37 (d, J = 8.4 Hz, 4H), 5.75 (s, 2H), 3.78–3.68 (m, 2H), 2.16 (s, 6H), 1.58–1.55 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 175.51, 153.08, 149.89, 149.48, 146.85, 142.44, 140.87, 133.41, 130.20, 129.67, 127.21, 127.19, 127.15, 119.01, 117.90, 116.45, 105.87, 105.85, 27.62, 20.25, 20.19, 20.10; HRMS (ESI) calcd for  $C_{44}H_{38}F_6N_2NaO_6$  (M + Na)<sup>+</sup> 827.2526, found 827.2520.

**Data for 11:** purple solid; yield, 36%; mp, >300 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 14.94 (d, J = 11.7 Hz, 2H), 10.41 (d, J = 11.7 Hz, 2H), 8.58 (s, 2H), 8.34 (s, 2H), 7.64 (d, J = 8.0 Hz, 4H), 7.52 (s, 2H), 7.29 (d, J = 8.0 Hz, 4H), 3.80–3.70 (m, 2H), 2.00 (s, 6H), 1.52–1.43 (m, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 174.71, 153.23, 146.68, 145.89, 139.81, 133.05, 129.55, 128.31, 127.85, 127.12, 121.85, 117.28, 115.75, 112.67, 106.31, 27.12, 20.72, 20.68; HRMS (ESI) calcd for  $C_{42}H_{39}N_2O_{12}S_2$  (M - 2Na + H)<sup>-</sup> 827.1950, found 827.1928.

**Data for 12:** yellow solid; yield, 72%; mp, 251–253 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.94 (d, J = 12.0 Hz, 2H), 10.10 (d, J = 12.0

Hz, 2H), 7.81 (s, 2H), 7.63 (s, 2H), 7.31 (d, J = 8.6 Hz, 4H), 7.22 (d, J = 8.6 Hz, 4H), 5.80 (s, 2H), 3.77–3.67 (m, 2H), 2.16 (s, 6H), 1.56–1.53 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 174.77, 153.99, 149.39, 146.89, 146.59, 138.27, 133.08, 129.97, 129.27, 122.66, 121.67, 119.30, 119.11, 118.84, 116.36, 114.22, 105.42, 27.59, 20.28, 20.24, 20.10; HRMS (ESI) calcd for  $C_{44}H_{37}F_6N_2O_8$  (M - H)<sup>-</sup> 835.2460, found 835.2441.

**Data for 13:** gold solid; yield, 91%; mp, 262–263 °C (lit.<sup>19</sup> 268–268 °C); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 14.67 (d, J = 12.7 Hz, 2H), 10.48 (s, 2H), 10.43 (d, J = 12.7 Hz, 2H), 8.68 (s, 2H), 8.21 (s, 2H), 7.51 (s, 2H), 7.33 (d, J = 8.1 Hz, 2H), 7.07–6.98 (m, 4H), 6.86 (t, J = 7.3 Hz, 2H), 3.78–3.70 (m, 2H), 2.00 (s, 6H), 1.49–1.44 (m, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 174.09, 150.90, 150.09, 147.37, 146.49, 132.15, 128.02, 127.73, 127.39, 125.84, 120.87, 119.94, 117.04, 115.99, 115.38, 114.71, 105.64, 26.56, 20.23, 20.21; HRMS (ESI) *m/z* calcd for  $C_{42}H_{39}N_2O_8$  (M - H)<sup>-</sup> 699.2712, found 699.2704.

**Data for 14:** orange crystal recrystallized from pyridine; yield, 56%; mp, 259–262 °C (lit.<sup>19</sup> 287 °C); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 14.86 (d, J = 12.0 Hz, 2H), 10.34 (d, J = 12.0 Hz, 2H), 9.82 (s, 2H), 8.57 (s, 2H), 8.32 (s, 2H), 7.51 (s, 2H), 7.22 (t, J = 8.1 Hz, 2H), 6.78–6.74 (m, 2H), 6.73 (t, J = 1.9 Hz, 2H), 6.63 (dd, J = 8.1, 1.9 Hz, 2H), 3.80–3.68 (m, 2H), 1.99 (s, 6H), 1.49–1.44 (m, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 174.04, 158.87, 152.99, 150.23, 146.21, 140.50, 132.42, 130.91, 128.80, 127.75, 121.20, 117.08, 115.31, 112.80, 108.52, 105.50, 104.19, 26.61, 20.20, 20.18; HRMS (ESI) *m/z* calcd for  $C_{42}H_{39}N_2O_8$  (M - H)<sup>-</sup> 699.2712, found 699.2704.

**Data for 15:** yellow solid; yield, 76%; mp, 252–254 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.75 (d, J = 12.8 Hz, 2H), 10.20 (d, J = 12.8 Hz, 2H), 7.97 (s, 2H), 7.63 (s, 2H), 7.37 (d, J = 7.5 Hz, 2H), 7.14 (t, J = 7.3 Hz, 2H), 6.98 (d, J = 7.8 Hz, 2H), 6.93 (t, J = 7.7 Hz, 2H), 5.76 (s, 2H), 4.03 (s, 6H), 3.78–3.69 (m, 2H), 2.15 (s, 6H), 1.58–1.52 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 174.31, 152.40, 149.78, 149.39, 147.18, 132.64, 129.78, 128.83, 128.29, 126.13, 121.27, 118.61, 116.20, 115.50, 114.52, 111.49, 105.41, 56.19, 27.53, 20.33, 20.28, 20.12; HRMS (ESI) calcd for  $C_{44}H_{43}N_2O_8$  (M - H)<sup>-</sup> 727.3025, found 727.3002.


**Data for 16:** yellow solid; yield, 83%; mp, 266–268 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.82 (d, J = 12.2 Hz, 2H), 10.14 (d, J = 12.2 Hz, 2H), 7.87 (s, 2H), 7.63 (s, 2H), 7.26–7.23 (t, J = 8.0 Hz, 2H), 6.89 (dd, J = 8.0, 1.4 Hz, 2H), 6.81 (s, 2H), 6.71 (dd, J = 8.0, 1.4 Hz, 2H), 5.83 (s, 2H), 3.79 (s, 6H), 3.76–3.67 (m, 2H), 2.15 (s, 6H), 1.57–1.52 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 174.33, 160.83, 154.04, 149.42, 146.94, 140.61, 132.82, 130.69, 129.73, 128.86, 118.66, 116.38, 114.40, 111.27, 110.48, 105.07, 104.17, 55.45, 27.56, 20.29, 20.13; HRMS (ESI) calcd for  $C_{44}H_{43}N_2O_8$  (M - H)<sup>-</sup> 727.3025, found 727.3009.

**Data for 17:** orange solid; yield, 97%; mp, 255–257 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 14.89 (d, J = 12.8 Hz, 2H), 10.13 (d, J = 12.8 Hz, 2H), 7.99 (s, 2H), 7.63 (s, 2H), 7.27 (d, J = 8.8 Hz, 2H), 6.54 (d, J = 2.4 Hz, 2H), 6.44 (dd, J = 8.8, 2.4 Hz, 2H), 5.76 (s, 2H), 3.99 (s, 6H), 3.79 (s, 6H), 3.77–3.69 (m, 2H), 2.15 (s, 6H), 1.57–1.52 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), δ 173.35, 158.65, 152.58, 151.01, 149.33, 147.22, 132.35, 129.51, 127.85, 122.56, 118.46, 116.56, 116.06, 114.60, 105.06, 104.97, 99.27, 56.22, 55.63, 27.51, 20.38, 20.33, 20.14; HRMS (ESI) calcd for  $C_{46}H_{47}N_2O_{10}$  (M - H)<sup>-</sup> 787.3236, found 787.3236.

**Data for 18:** gold solid; yield, 89%; mp, 234–235 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>), δ 14.62 (d, J = 11.6 Hz, 2H), 10.39 (d, J = 11.6 Hz, 2H), 8.72 (s, 2H), 8.35 (s, 2H), 7.52 (s, 2H), 7.12 (d, J = 6.8 Hz, 2H), 6.92 (s, 2H), 6.77 (d, J = 6.8 Hz, 2H), 3.90 (s, 6H), 3.69 (br s, 8H), 1.98 (s, 6H), 1.46 (br s, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ 174.76, 154.00, 150.79, 150.35, 146.52, 143.23, 132.48, 129.00, 128.66, 128.00, 120.80, 117.14, 115.03, 113.19, 109.66, 106.21, 101.40, 56.49, 55.59, 26.61, 20.18; HRMS (ESI) calcd for  $C_{46}H_{47}N_2O_{10}$  (M - H)<sup>-</sup> 787.3236, found 787.3219.

**Data for 19:** chocolate solid; yield, 43%; mp, 251–253 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 15.21 (d, J = 11.0 Hz, 2H), 10.10 (d, J = 11.0 Hz, 2H), 7.74 (s, 2H), 7.68 (d, J = 7.7 Hz, 2H), 7.62 (s, 2H), 7.53 (t, J = 7.7 Hz, 2H), 7.46 (d, J = 7.7 Hz, 2H), 7.26 (t, J = 7.7 Hz, 2H),

Scheme 1. General Synthetic Route for Target Compounds 3–25



5.77 (s, 2H), 3.76–3.66 (m, 2H), 2.15 (s, 6H), 1.57–1.51 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  174.94, 154.82, 149.50, 146.83, 138.56, 133.50, 133.34, 130.21, 129.54, 127.10, 127.05, 126.99, 126.94, 125.26, 125.00, 122.28, 121.15, 120.85, 119.03, 118.92, 116.41, 114.15, 106.43, 27.59, 20.23, 20.19, 20.12; HRMS (ESI) calcd for  $\text{C}_{44}\text{H}_{37}\text{F}_6\text{N}_2\text{O}_6$  ( $\text{M} - \text{H}$ ) $^-$  803.2561, found 803.2533.

**Data for 20:** yellow solid; yield, 81%; mp, 262–264 °C (lit.<sup>21</sup> 216–217.5 °C);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  15.02 (d,  $J = 11.7$  Hz, 2H), 10.14 (d,  $J = 11.7$  Hz, 2H), 7.79 (s, 2H), 7.65 (s, 2H), 7.54–7.41 (m, 8H), 5.79 (s, 2H), 3.77–3.69 (m, 2H), 2.16 (s, 6H), 1.58–1.53 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  175.19, 153.49, 149.49, 146.87, 140.23, 133.31, 133.11, 132.66, 132.32, 131.98, 130.54, 130.12, 129.55, 124.89, 122.18, 122.14, 122.10, 121.16, 118.97, 116.44, 114.91, 114.87, 114.11, 105.69, 27.63, 20.27, 20.24, 20.12; HRMS (ESI) calcd for  $\text{C}_{44}\text{H}_{37}\text{F}_6\text{N}_2\text{O}_6$  ( $\text{M} - \text{H}$ ) $^-$  803.2561, found 903.2543.

**Data for 21:** yellow crystal recrystallized from petroleum ether and ethyl acetate; yield, 49%; mp, 221–223 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  15.12 (d,  $J = 11.6$  Hz, 2H), 10.10 (d,  $J = 11.6$  Hz, 2H), 7.72–7.62 (m, 10H), 5.85 (s, 2H), 3.89–3.58 (m, 2H), 2.17 (s, 6H), 1.57–1.51 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  175.87, 152.50, 149.68, 146.72, 141.32, 133.99, 133.93, 133.66, 133.32, 130.49, 130.45, 124.15, 121.44, 119.22, 118.41, 117.71, 116.73, 113.77, 106.48, 27.71, 20.20, 20.17; HRMS (ESI) calcd for  $\text{C}_{46}\text{H}_{35}\text{F}_{12}\text{N}_2\text{O}_6$  ( $\text{M} - \text{H}$ ) $^-$  939.2309, found 939.2283.

**Data for 22:** orange-red crystal recrystallized from pyridine and ethanol; yield, 62%; mp, 269–270 °C (lit.<sup>19</sup> 280–282 °C);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  15.03 (d,  $J = 11.6$  Hz, 2H), 10.16 (d,  $J = 11.6$  Hz, 2H), 8.15 (s, 2H), 8.00 (d,  $J = 7.5$  Hz, 2H), 7.73 (s, 2H), 7.66 (s, 2H), 7.62–7.50 (m, 4H), 5.79 (s, 2H), 3.76–3.70 (m, 2H), 2.17 (s, 6H), 1.56 (br s, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  175.68, 152.92, 149.84, 149.57, 149.37, 146.75, 141.03, 133.63, 130.80, 130.32,

130.10, 124.12, 119.80, 119.13, 116.55, 112.09, 106.15, 27.65, 20.22, 20.20, 20.14.

**Data for 23:** yellow solid; yield, 65%; mp, >300 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ),  $\delta$  14.93 (d,  $J = 12.2$  Hz, 2H), 10.42 (d,  $J = 12.2$  Hz, 2H), 8.66 (s, 2H), 8.62 (s, 2H), 7.69 (s, 2H), 7.48 (s, 2H), 7.43 (d,  $J = 8.5$  Hz, 2H), 7.14 (d,  $J = 8.5$  Hz, 2H), 3.97 (s, 6H), 3.80–3.68 (m, 2H), 1.97 (s, 6H), 1.51–1.41 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}-d_6$ ),  $\delta$  174.48, 150.97, 150.68, 149.01, 146.23, 141.88, 132.34, 128.66, 127.72, 127.38, 123.09, 121.61, 116.97, 115.30, 112.34, 111.12, 106.29, 56.38, 26.61, 20.32, 20.22, 20.19; HRMS (ESI) calcd for  $\text{C}_{44}\text{H}_{43}\text{N}_2\text{O}_{14}\text{S}_2$  ( $\text{M} - 2\text{Na} + \text{H}$ ) $^-$  887.2161, found 887.2121.

**Data for 24:** orange-red crystal recrystallized from pyridine and ethanol; yield, 82%; mp, 281 °C (lit.<sup>19</sup> 302–303 °C);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  15.17 (d,  $J = 12.2$  Hz, 2H), 10.32 (d,  $J = 12.2$  Hz, 2H), 7.92 (s, 2H), 7.84 (d,  $J = 8.8$  Hz, 2H), 7.78 (d,  $J = 7.4$  Hz, 4H), 7.69 (s, 2H), 7.67 (s, 2H), 7.51–7.38 (m, 6H), 5.85 (s, 2H), 3.82–3.70 (m, 2H), 2.19 (s, 6H), 1.59–1.55 (m, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  174.36, 153.88, 149.81, 149.44, 147.01, 136.86, 133.82, 132.88, 131.46, 130.09, 129.82, 128.80, 127.85, 127.50, 127.25, 125.79, 118.74, 117.41, 116.31, 115.22, 105.33, 27.57, 20.33, 20.28, 20.14.

**Data for 25:** orange-red solid; yield, 86%; mp, 280–281 °C (lit.<sup>19</sup> 283–285.5 °C);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ),  $\delta$  15.88 (d,  $J = 11.6$  Hz, 2H), 10.36 (d,  $J = 11.6$  Hz, 2H), 8.36 (d,  $J = 8.4$  Hz, 2H), 7.99 (s, 2H), 7.91 (d,  $J = 8.4$  Hz, 2H), 7.75–7.70 (m, 4H), 7.68 (s, 2H), 7.60 (t,  $J = 7.5$  Hz, 2H), 7.52 (d,  $J = 7.4$  Hz, 2H), 7.44 (t,  $J = 7.8$  Hz, 2H), 5.86 (s, 2H), 3.85–3.73 (m, 2H), 2.20 (s, 6H), 1.60 (t,  $J = 6.1$  Hz, 12H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  174.30, 155.54, 149.84, 149.54, 147.03, 136.11, 135.94, 134.22, 132.86, 129.76, 128.93, 128.55, 127.34, 126.89, 126.38, 125.74, 125.59, 123.72, 121.22, 118.69, 116.31, 114.44, 113.69, 105.89, 27.59, 20.34, 20.29, 20.15.




Figure 3.  $^1\text{H}$  NMR spectra of compound 5.

**Biological Assay.** The anti-TMV activity of all compounds was tested using our previously reported methods.<sup>22</sup>

The field trials were carried out in the trial area of the Institute of Agricultural Environment and Resource, Yunnan Academy of Agricultural Sciences, Kunming City, China, between June and July 2014. The formulation of compound 19 (1% emulsifiable concentrates (EC)) was prepared in our research group. It was diluted to 750 L/ha before use.

The rat oral gavage acute toxicity of pesticides was performed in Xu He (Tianjin) Pharmaceutical Technology Co., Ltd. in May 2014. Sixteen rats, half males and half females, were divided randomly into four groups. The samples were respectively configured to 5 and 50 mg/mL.

## RESULTS AND DISCUSSION

**Chemistry.** Gossypol (1) was obtained using our previously reported method.<sup>23</sup> Gossypol acetic acid (2) was purchased from commercial sources. A series of Schiff bases of gossypol (3–25) were prepared by treating 2 with the corresponding amines in ethanol (Scheme 1). The Schiff bases had poor solubility in ethanol, so they were simply collected by filtration. Recrystallization of the products from suitable solvents could give purer samples. Unfortunately, recrystallization was not fit for compounds 15–18 and 20. However, they were obtained via the employment of excess amine when the preparation was repeated. For compounds 11 and 23, the sulfonic sodium salts of corresponding amines were prepared from homologous aminobenzenesulfonic acid and NaOH, for which were used 3 equiv of gossypol to ensure them a sodium sulfonate group. It is worth mentioning that if there are multiple electron withdrawing groups on the ortho and para positions of aromatic amine, such as 2,4-dinitroaniline and 2-nitro-4-(trifluoromethyl)aniline, the corresponding Schiff base of gossypol could not be achieved but the dehydration product of gossypol, anhydrogossypol,<sup>24</sup> was obtained. All of our synthetic gossypol Schiff bases exist in the enamine–enamine form<sup>15,25</sup> in solution as determined by  $^1\text{H}$  NMR. For compound 5, for example, the structure can be interpreted by the  $^1\text{H}$  NMR spectrum (Figure 3). The signal peaks of

symmetrical protons should appear at the same position and have identical coupling constants because of the axial symmetry of the structure. The presence of doublet peaks with the coupling constant of 12.0 Hz in the  $^1\text{H}$  NMR spectrum can be attributed to the signals of  $\text{H}-\text{C}=\text{C}$  proton (j) and  $\text{H}-\text{NAr}$  proton (k). This behavior can be rationally explained by the fact that two protons are adjacent and coupled with each other.

**Antiviral Biological Assay.** Compounds 1–25 were initially tested for their phytotoxic activities against the test plant, *Nicotiana tabacum* L. The results indicated that these natural product-based compounds showed no phytotoxic activity at 500  $\mu\text{g}/\text{mL}$ . In other words, the compounds caused no harm to the test plant; therefore, there would be no interference with the determination of anti-TMV data.

The antiviral bioassay of the compounds against TMV was carried out, and the antiviral results are listed in Tables 1 and 2. To make a judgment on the antiviral potency of the synthesized compounds, the commercially available plant virucide ribavirin<sup>24</sup> was used as the control.

The in vitro anti-TMV activities of compounds 1–25 and the contrast compound ribavirin are shown in Table 1. The results indicate that these target compounds exhibit moderate to excellent activities against TMV. Among these compounds, gossypol (1) and gossypol acetic acid (2) displayed similar in vitro anti-TMV activities (1, 32%; 2, 28%); however, they were less effective than ribavirin (38%) at 500  $\mu\text{g}/\text{mL}$ . In contrast, except for 6, 22, and 24, other aromatic gossypol Schiff bases of 3–25 showed equivalent or even higher antiviral activities than ribavirin (38%); especially compounds 5, 9, 10, 12, 15, 17, 19, and 23 displayed obviously higher anti-TMV activities at a concentration of 500  $\mu\text{g}/\text{mL}$ , and the antiviral activities of compounds 9 and 19 at 100  $\mu\text{g}/\text{mL}$  even reach the level of ribavirin at 500  $\mu\text{g}/\text{mL}$ .

On comparison with the parent dianilinogossypol (3), except for *p*-hydroxy compound 6, the activities of Schiff bases 4–12 with different substituent groups on the para position of aniline are higher. However, they displayed distinctly different activity levels against TMV in vitro. Compounds with methoxy (5),

**Table 1. In Vitro Antiviral Activity of Compounds 1–25 and Ribavirin against TMV**

compd	concn ( $\mu\text{g/mL}$ )	in vitro curative effect (%)	compd	concn ( $\mu\text{g/mL}$ )	in vitro curative effect (%)
	100	0		100	0
2	500	28	15	500	58
	100	0		100	14
3	500	32	16	500	40
	100	0		100	0
4	500	40	17	500	53
	100	0		100	22
5	500	47	18	500	30
	100	10		100	0
6	500	24	19	500	62
	100	0		100	32
7	500	37	20	500	39
	100	6		100	0
8	500	44	21	500	32
	100	0		100	0
9	500	50	22	500	26
	100	39		100	0
10	500	57	23	500	47
	100	20		100	18
11	500	40	24	500	25
	100	0		100	0
12	500	52	25	500	44
	100	20		100	16
13	500	33	ribavirin	500	38
	100	0		100	14

nitro (**9**), trifluoromethyl (**10**), and trifluoromethoxy (**12**) showed excellent activities (48, 50, 57, and 52%, respectively). To investigate the influence of the position and the number of substituents on the activities, **13**–**23** were synthesized. Compared with their para-substitutional substrates, corresponding substituent groups on the ortho position were beneficial to the increase of their anti-TMV activities, whereas the substituent groups on meta positions were unfavorable to the anti-TMV activities (MeO, **15** > **5** > **16**; CF<sub>3</sub>, **19** > **10** > **20**; NO<sub>2</sub>, **9** > **22**). However, the substituent group of the hydroxyl was an exception, as the *o*-hydroxyl compound **13** and *m*-hydroxyl compound **14** had higher activities than *p*-hydroxyl compound **6**. Furthermore, the level of the anti-TMV activities could not be improved by increasing the number of substituent groups. Among methoxy-substituted compounds **5** and **15**–**18**, **15** with only one substituent group on the ortho position displayed the best inhibitory effect. However, **23** (18%) with *o*-methoxy and *m*-sodium sulfonate substituent groups exhibited better inhibitory effect than **11** (0%) and **15** (14%) at 100  $\mu\text{g}/$

**Table 2. In Vivo Anti-TMV Activity of Compounds 1–25 and Ribavirin**

compd	concn ( $\mu\text{g/mL}$ )	in vivo activity		
		inactivation effect (%)	curative effect (%)	protection effect (%)
1	500	35	29	29
	100	8	0	0
2	500	32	30	33
	100	0	0	0
3	500	52	34	44
	100	27	0	27
4	500	8	37	50
	100	0	0	17
5	500	46	42	44
	100	19	20	21
6	500	20	17	23
	100	0	0	0
7	500	33	36	35
	100	11	0	9
8	500	36	41	43
	100	9	19	20
9	500	36	47	42
	100	12	40	22
10	500	35	51	42
	100	25	22	19
11	500	38	35	36
	100	0	0	9
12	500	54	50	56
	100	26	21	23
13	500	35	36	34
	100	10	0	9
14	500	40	34	38
	100	10	8	15
15	500	51	55	56
	100	16	20	27
16	500	46	43	48
	100	18	9	23
17	500	56	48	50
	100	28	19	23
18	500	36	33	36
	100	8	0	0
19	500	60	57	62
	100	23	30	26
20	500	52	35	48
	100	17	13	22
21	500	41	35	37
	100	12	0	9
22	500	26	23	34
	100	0	0	0
23	500	46	43	38
	100	17	13	15
24	500	37	28	30
	100	8	0	0
25	500	39	37	43
	100	10	19	16
ribavirin	500	38	37	40
	100	12	17	18

mL. The Schiff bases of naphthylamines were synthesized as well, and their anti-TMV activities were performed. Compound **25** (44% at 500  $\mu\text{g/mL}$ ), obtained by the condensation of gossypol and 1-naphthylamine, displayed a better inhibitory

effect than dianilinogossypol (3, 32% at 500  $\mu\text{g}/\text{mL}$ ). At variance with 25, the activity of 2-naphthylamine Schiff base 24 (25% at 500  $\mu\text{g}/\text{mL}$ ) was relatively lower than that of 3.

Due to their well-performed behaviors of *in vitro* antiviral activities against TMV, the *in vivo* antiviral activities of these compounds deserve to be exploited further. As shown in Table 2, the majority of the compounds also displayed equivalent or higher *in vivo* activities than the control ribavirin at a concentration of 500  $\mu\text{g}/\text{mL}$ . In particular, Schiff bases 12, 15, 17, and 19 exhibited obviously higher anti-TMV activities than ribavirin at 500  $\mu\text{g}/\text{mL}$ , of which compound 19 with an *o*-trifluoromethyl group showed the best activity (inactivation activity, 60%/500  $\mu\text{g}/\text{mL}$  and 23%/100  $\mu\text{g}/\text{mL}$ ; curative activity, 57%/500  $\mu\text{g}/\text{mL}$  and 30%/100  $\mu\text{g}/\text{mL}$ ; and protection activity, 62%/500  $\mu\text{g}/\text{mL}$  and 26%/100  $\mu\text{g}/\text{mL}$ ), confirmed by the *in vivo* inactivation tests, curative tests, and protection tests. Additionally, the *in vivo* curative activities of these compounds displayed structure–activity relationships similar to the activities *in vitro*. More importantly, compound 9 with a *p*-nitro group showed a better effect at 100  $\mu\text{g}/\text{mL}$  (40%), which is even higher than that of ribavirin at 500  $\mu\text{g}/\text{mL}$  (37%).

Interestingly, the *in vivo* inactivation and protection activities of dianilinogossypol (3) displayed excellent inhibitory effects (inactivation activity, 52%/500  $\mu\text{g}/\text{mL}$  and 27%/100  $\mu\text{g}/\text{mL}$ ; protection activity, 44%/500  $\mu\text{g}/\text{mL}$  and 27%/100  $\mu\text{g}/\text{mL}$ ). However, only 12, 15, 17, 19, and 20 exhibited obviously better *in vivo* curative and protection activities at 500  $\mu\text{g}/\text{mL}$  than parent dianilinogossypol (3). These results indicated the introduction of trifluoromethoxy, methoxy, and trifluoromethyl on the aromatic ring of aniline could increase the anti-TMV activities level of parent dianilinogossypol. Further analysis of the relationship between the positions of substituents and anti-TMV activities indicated that the order of methoxy and trifluoromethyl is ortho > meta > para position (15 > 16 > 5, 19 > 20 > 10). Other groups and the number of them displayed similar SAR to anti-TMV activities *in vitro*. The derivatives of naphthylamines (24 and 25) had lower inhibitory effect than dianilinogossypol (3), but 1-naphthylamine (25) is relatively higher than that of 2-naphthylamine (24).

#### Evaluation of Anti-TMV Activity of 19 in the Field.

Compound 19, which had exhibited the best anti-TMV activity both *in vitro* and *in vivo* in the laboratory, was employed to evaluate the antiviral activity in the field. A 1% EC solution of 19 was prepared and evaluated for the control of TMV in Tengchong county of Yunnan province (southern China). The results of the field trials are shown in Table 3, which indicated that 19 at the amount of 10 g ai/ha had the same control effect (about 66%) as 5% amino glycan at 100 g ai/ha and 20% moroxydine hydrochloride–cupric acetate at 600 g ai/ha at 10 days after spraying. Therefore, it was suggested that 19 could be considered as an alternative to the employed plant virus inhibitor for further development on the basis of the field trials.

Table 3. Anti-TMV Effect in the Field in 2014

compd	amount (g ai/ha)	controlled effect (%)
19	10	66.61
	50	83.88
	100	94.56
5% amino glycan	100	65.70
20% moroxydine hydrochloride–cupric acetate	600	66.57

#### Rat Oral Gavage Acute Toxicity of Gossypol and 19.

To balance the toxicity versus efficacy of compound 19, we next explored the tolerated dose of 19 and gossypol using a group of rats. They were treated with a single dose of 500 or 50 mg/kg and observed for a period of 14 days, monitoring morbidity (body weight loss) and mortality. All rats were alive after 14 days. The weight of the rats that were treated with gossypol at 500 mg/kg slightly declined over the first 6 days. There is no obvious weight difference between any other two groups (Figure 4). Therefore, gossypol and 19 display low toxicity to rats, but the toxicity of 19 is lower.




Figure 4. Average weight of rats. Gossypol-L, dosage of gossypol is 50 mg/kg; gossypol-H, dosage of gossypol is 500 mg/kg; 19-L, dosage of 19 is 50 mg/kg; 19-H, dosage of 19 is 500 mg/kg.

In summary, to eliminate the toxicity caused by the aldehyde group, retain the electron transfer functionalities to generate ROS, and adjust the anti-TMV activity level of gossypol, a series of aromatic gossypol Schiff bases 3–25 were prepared and investigated for their anti-TMV activity for the first time. The bioassay results indicated that most of these Schiff bases showed moderate to excellent activities against TMV and were more effective than gossypol (1) and gossypol acetic acid (2). The introduction of methoxy, trifluoromethyl, or trifluoromethoxy groups, positioned ortho to amine of enamine, could significantly increase the anti-TMV activity levels. Among all of the compounds, compound 19 with an *o*-trifluoromethyl group showed the best anti-TMV activities both *in vitro* and *in vivo* in the laboratory. Furthermore, the compound at 10 g ai/ha in the field trial had the same control effect as 5% amino glycan at 100 g ai/ha and 20% moroxydine hydrochloride–cupric acetate at 600 g ai/ha. More importantly, it showed lower toxicity to rats than gossypol. Because of the easy preparation, good anti-TMV activity, and low toxicity, the *o*-trifluoromethylaniline Schiff base (19) is expected to be developed as a promising candidate as an inhibitor of plant virus. Further studies on structural optimization and mechanism of action are currently underway in our laboratory.

#### ASSOCIATED CONTENT

##### Supporting Information

Fungicidal, insecticidal, and herbicidal activities. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Author

\*(Q.W.) Phone: +86-(0)22-23503952. Fax: +86-(0)22-23503952. E-mail: wang98h@263.net or wangqm@nankai.edu.cn.

### Funding


We are grateful to the National Natural Science Foundation of China (21132003, 21121002, 21372131), the Specialized Research Fund for the Doctoral Program of Higher Education (20120031110010), and the Science Technology Plan Project of China Tobacco Yunnan Co. (2012YN08) for generous financial support for our programs.

### Notes

The authors declare no competing financial interest.

## REFERENCES

- (1) (a) Vermel, E. M.; Kruglyak, S. A. Anticancer activity of some alkaloids. *Vopr. Onkol.* **1962**, *8*, 9–17. (b) Wang, G.; Nikolovska-Coleska, Z.; Yang, C. Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Aabaan, H. O.; Tomita, Y.; Wang, S. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. *J. Med. Chem.* **2006**, *49*, 6139–6142. (c) Meng, Y.; Tang, W.; Dai, Y.; Wu, X.; Liu, M.; Ji, Q.; Ji, M.; Pienta, K.; Lawrence, T.; Xu, L. Natural BH3 mimetic (–)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. *Mol. Cancer Ther.* **2008**, *7*, 2192–2202. (d) Wang, X.; Howell, C. P.; Chen, F.; Yin, J.; Jiang, Y. Gossypol – a polyphenolic compound from cotton plant. *Adv. Food Nutr. Res.* **2009**, *58*, 215–263.
- (2) Campbell, K. N.; Morris, R. C.; Adams, R. The structure of gossypol. *J. Am. Chem. Soc.* **1937**, *59*, 1723–1728.
- (3) (a) Abraham, K. J.; Pierce, M. L.; Essenberg, M. The phytoalexins desoxyhemigossypol and hemigossypol are elicited by *Xanthomonas* in *Gossypium* cotyledons. *Phytochemistry* **1999**, *52*, 829–836. (b) Liu, J.; Benedict, C. R.; Stipanovic, R. D.; Bell, A. A. Purification and characterization of S-adenosyl-L-methionine: desoxyhemigossypol-6-O-methyltransferase from cotton plants. *Plant Physiol.* **1999**, *121*, 1017–1024. (c) Puckhaber, L. S.; Dowd, M. K.; Stipanovic, R. D.; Howell, C. R. Toxicity of (+) and (–)-gossypol to the plant pathogen *Rhizoctonia solani*. *J. Agric. Food Chem.* **2002**, *50*, 7017–7021.
- (4) Stipanovic, R. D.; Altman, D. W.; Begin, D. L.; Greenblatt, G. A.; Benedict, J. H. Terpenoid aldehydes in upland cottons: analysis by aniline and HPLC methods. *J. Agric. Food Chem.* **1988**, *36*, 509–515.
- (5) (a) Yang, J.; Chen, G.; Li, L. L.; Pan, W.; Zhang, F.; Yang, J.; Wu, S.; Tien, P. Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2619–2623. (b) Yang, J.; Zhang, F.; Li, J. R.; Chen, G.; Wu, S. W.; Ouyang, W. J.; Pan, W.; Yu, R.; Yang, J. X.; Tien, P. Synthesis and antiviral activities of novel gossypol derivatives. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 1415–1420.
- (6) (a) Wichmann, K.; Vaheri, A.; Luukkainen, T. Inhibiting herpes simplex virus type 2 infection in human epithelial cells by gossypol, a potent spermicidal and contraceptive agent. *Am. J. Obstet. Gynecol.* **1982**, *142*, 593–594. (b) Radloff, R. J.; Deck, L. M.; Royer, R. E.; Vander Jagt, D. L. Antiviral activities of gossypol and its derivatives against herpes simplex virus type II. *Pharmacol. Res. Commun.* **1986**, *18*, 1063–1067.
- (7) Vichkanova, S. A.; Oifa, A. I.; Goryunova, L. V. Antiviral properties of gossypol in experimental influenza pneumonia. *Antibiotiki* **1970**, *15*, 1071–1073.
- (8) Wu, Y. F. A mixture of polyhydroxy binaphthaldehyde and fatty acid used as a novel broad-spectrum agricultural antiviral agent and its preparation method. CN1489904A, 2004.
- (9) Ritzenthaler, C. Resistance to plant viruses: old issue, news answers? *Curr. Opin. Biotechnol.* **2005**, *16*, 118–122.
- (10) (a) Ouyang, G. P.; Cai, X. J.; Chen, Z.; Song, B. A.; Bhadury, P. S.; Yang, S.; Jin, L. H.; Xue, W.; Hu, D. Y.; Zeng, S. Synthesis and antiviral activities of pyrazole derivatives containing an oxime moiety. *J. Agric. Food Chem.* **2008**, *56*, 10160–10167. (b) Chen, M. H.; Chen, Z.; Song, B. A.; Bhadury, P. S.; Yang, S.; Cai, X. J.; Hu, D. Y.; Xue, W.; Zeng, S. Synthesis and antiviral activities of chiral thiourea derivatives containing an  $\alpha$ -aminophosphonate moiety. *J. Agric. Food Chem.* **2009**, *57*, 1383–1388. (c) Li, Y. M.; Zhang, Z. K.; Jia, Y. T.; Shen, Y. M.; He, H. P.; Fang, R. X.; Chen, X. Y.; Hao, X. J. 3-Acetyl-3-hydroxyoxindole: a new inducer of systemic acquired resistance in plants. *Plant Biotechnol. J.* **2008**, *6*, 301–308. (d) Bachrach, U. Antiviral activity of oxidized polyamines. *Amino Acids* **2007**, *33*, 267–272. (e) Su, B.; Chen, F.; Wang, L.; Wang, Q. Design, synthesis, antiviral activity, and structure–activity relationships (SARs) of two types of structurally novel phenanthroindo/quinolizidine analogues. *J. Agric. Food Chem.* **2014**, *62*, 1233–1239. (f) Song, H.; Liu, Y.; Liu, Y.; Wang, L.; Wang, Q. Synthesis and antiviral and fungicidal activity evaluation of  $\beta$ -carboline, dihydro- $\beta$ -carboline, tetrahydro- $\beta$ -carboline alkaloids, and their derivatives. *J. Agric. Food Chem.* **2014**, *62*, 1010–1018.
- (11) Dodou, K. Investigations on gossypol: past and present developments. *Expert Opin. Invest. Drugs* **2005**, *14*, 1419–1434.
- (12) Kovacic, P. Mechanism of drug and toxic actions of gossypol: focus on reactive oxygen species and electron transfer. *Curr. Med. Chem.* **2003**, *10*, 2711–2718.
- (13) Bacsó, R. Y.; Hafez, M.; Király, Z.; Király, L. Inhibition of virus replication and symptom expression by reactive oxygen species in tobacco infected with tobacco mosaic virus. *Acta Phytopathol. Entomol.* **2011**, *46*, 1–10.
- (14) Kenar, J. A. Reaction chemistry of gossypol and its derivatives. *J. Am. Oil Chem. Soc.* **2006**, *83*, 269–302.
- (15) Przybylski, P.; Huczynski, A.; Pyta, K.; Brzezinski, B.; Bartl, F. Biological properties of Schiff bases and azo derivatives of phenols. *Curr. Org. Chem.* **2009**, *13*, 124–148.
- (16) (a) Przybylski, P.; Pyta, K.; Remlein-Starosta, D.; Schroeder, G.; Brzezinski, B.; Bartl, F. Antifungal activity of alkyl and heterocyclic azo-derivatives of gossypol as well as their complexes with NaClO<sub>4</sub> against *Fusarium oxysporum* f. sp. *lupini*. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1996–2000. (b) Zhang, L.; Jiang, H.; Cao, X.; Zhao, H.; Wang, F.; Cui, Y.; Jiang, B. Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling. *Eur. J. Med. Chem.* **2009**, *44*, 3961–3972. (c) Przybylski, P.; Pyta, K.; Stefanska, J.; Ratajczak-Sitarz, M.; Katrusiak, A.; Huczynski, A.; Brzezinski, B. Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant – gossypol. *Eur. J. Med. Chem.* **2009**, *44*, 4393–4403.
- (17) Baram, N. I.; Biktimirov, L.; Dzhurabekova, S. B.; Kamaev, F. G.; Ismailov, A. I. Imines of gossypol ethers. *Chem. Nat. Compd.* **1991**, *27*, 309–312.
- (18) Przybylski, P.; Maluszynska, M.; Brzezinski, B. Spectroscopic and semiempirical studies of new Schiff base of gossypol with allylamine in solution. *J. Mol. Struct.* **2005**, *750*, 152–157.
- (19) Dechary, J. M.; Brown, L. E. Substituted arylimino derivatives of gossypol. *J. Am. Oil Chem. Soc.* **1956**, *33*, 76–78.
- (20) (a) That, Q. T.; Nguyen, K. P. P.; Hansen, P. E. Schiff bases of gossypol: an NMR and DFT study. *Magn. Reson. Chem.* **2005**, *43*, 302–308. (b) Zhou, X.; Wang, W.; Gu, J. NMR investigation of bis-4-fluoroaniline Schiff base of gossypol. *Acta Chim. Sinica* **1986**, *44*, 357–359.
- (21) Zhou, X.; Wang, W.; Gu, J. Novel fluorine-containing derivatives of gossypol. *Acta Chim. Sinica* **1988**, *46*, 375–378.
- (22) Wang, K. L.; Su, B.; Wang, Z. W.; Wu, M.; Li, Z.; Hu, Y. N.; Fan, Z. J.; Mi, N.; Wang, Q. M. Synthesis and antiviral activities of phenanthroindolizidine alkaloids and their derivatives. *J. Agric. Food Chem.* **2010**, *58*, 2703–2709.
- (23) Li, L.; Liu, Y. X.; Wang, Q. M. Regioselective oxidative dehydrogenation in nonenzymatic condition: a synthetic route to gossypol. *Eur. J. Org. Chem.* **2013**, *2013*, 8014–8021.
- (24) Structures of anhydrogossypol and ribavirin:
- (25) (a) Matlin, S. A.; Roshdy, S.; Cass, Q. B.; Freitas, L. C. G.; Longo, R. L.; Malvestiti, I. Structural investigations of gossypol Schiff's bases. *J. Braz. Chem. Soc.* **1990**, *1*, 128–133. (b) Przybylski, P.; Pyta,



K.; Ratajczak-Sitarz, M.; Katrusiak, A.; Brzezinski, B. Structure of a new Schiff base of gossypol with ethyl 4-amino-1-piperidine carboxylate in the solid and in the solution. *Polym. J. Chem.* **2009**, *83*, 747–759. (c) Przybylski, P.; Schilf, W.; Kamienski, B.; Brzezinski, B.; Bartl, F. CP/MAS spectroscopy in the determination of the tautomeric forms of gossypol, its Schiff bases and hydrazones in the solid state. *Magn. Reson. Chem.* **2008**, *46*, 534–544. (d) Ilkevych, N. S.; Schroeder, G.; Rybachenko, V. I.; Chotiy, K. Y.; Makarova, R. A. Vibrational spectra, structure and antioxidant activity of gossypol imine derivatives. *Spectrochim. Acta Part A* **2012**, *86*, 328–335.